• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Cellectis Inc.

< Previous 1 2 3 Next >
News headline image
FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment
August 01, 2024
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment
July 25, 2024
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024
June 28, 2024
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing
June 20, 2024
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
June 12, 2024
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia
June 04, 2024
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024
May 29, 2024
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Reports Financial Results for First Quarter 2024
May 28, 2024
From Cellectis Inc.
Via GlobeNewswire
Tickers AZN CLLS
News headline image
Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024
May 27, 2024
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
May 06, 2024
From Cellectis Inc.
Via GlobeNewswire
Tickers AZN CLLS
News headline image
Cellectis Appoints Arthur Stril as Interim Chief Financial Officer
May 02, 2024
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023
April 29, 2024
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs
April 22, 2024
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
April 10, 2024
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting
April 08, 2024
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)
January 16, 2024
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023
December 22, 2023
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis’ Shareholders Meeting to be Held on December 22, 2023
November 17, 2023
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca
November 15, 2023
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023
November 06, 2023
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting
November 02, 2023
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023
November 01, 2023
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca
November 01, 2023
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
October 31, 2023
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis to Present Pre-Clinical Data on HSPC Gene Therapy Program and Comprehensive Analysis of TALE-BE at the ESGCT 30th Annual Congress
October 24, 2023
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of a Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase Δ Syndrome Type 1 (APDS1)
October 12, 2023
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
September 27, 2023
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Provides Full Report for Second Quarter 2023 Financial Results
August 07, 2023
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Provides Business Updates and Preliminary Financial Results for Second Quarter 2023
August 03, 2023
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis to Report Second Quarter 2023 Financial Results on August 3, 2023
July 27, 2023
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap